Potential of the Introduction of Tedizolid for the Treatment of Complicated Skin and Soft Tissue Infections in a Russian Multi-Field Hospital

Abstract

Increase in prevalence of methicillin-resistant Staphylococcus aureus (MRSA) strains among the pathogens of complicated skin and soft tissue infections (cSSTIs) in hospitalised patients demands introduction of new treatment options with improved efficacy and safety into clinical practice such as novel oxazolidinone antibiotic — tedizolid. We aimed to assess impact of introduction of tedizolid for the treatment of hospitalized patients with cSSTIs presumptively сaused by MRSA on the budget of a Russian multi-field hospital. The budget for the treatment of presumptive MRSA cSSTIs in a hypothetic cohort of 100 hospitalised patients with the current mix of treatment options amounts to 4,865,665 RUB. Replacement of 25% of linezolid by tedizolid leads to total budget decrease of 105,656 RUB, 50% — of 212,374 RUB, 100% — of 428,996 RUB and hospital bed usage optimisation by 1.9%, 3.9% and 8.1% respectively.

Keywords

• complicated skin and soft tissue infection
• cssti
• tedizolid
• methicillin-resistant staphylococcus aureus
• mrsa
• budget impact analysis